Chargement en cours...

The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer

Immune checkpoint inhibitors (ICIs) are newer therapies being applied to an increasing number of patients with cancer. Data suggest that up to 36% of cancer patients may be eligible for immunotherapy and, in late 2019, there were more than 3,362 clinical trials initiated to evaluate the effectivenes...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JACC CardioOncol
Auteurs principaux: Zhang, Lili, Reynolds, Kerry L., Lyon, Alexander R., Palaskas, Nicolas, Neilan, Tomas G.
Format: Artigo
Langue:Inglês
Publié: Elsevier 2021
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8034586/
https://ncbi.nlm.nih.gov/pubmed/33842895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaccao.2020.11.012
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!